VeraDermics Inc (MANE)
NYSEHealth CareBiotechnologySnapshot 2026-11-05
$128.60-5.79%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · MANE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
"With enrollment in Study ‘306’ now complete, we look forward to a catalyst-rich remainder of 2026 as we progress toward topline data from the confirmatory Phase 3 Study ‘304’ in men and 12-month dat…
Stated in 2 of 2 supplied quarters. Management reported: “• Phase 3 Study ‘304’; Topline Data Anticipated in 2H26: T opline data from Study ‘304’, a confirmatory Phase 3 trial evaluating the safety and efficacy of VDPHL01 in the treatment of male pattern hair loss, are expected in the second half of 2026.” “Twelve-month data from Study ‘302’ are anticipated in the second half of 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“"With enrollment in Study ‘306’ now complete, we look forward to a catalyst-rich remainder of 2026 as we progress toward topline data from the confirmatory Phase 3 Study ‘304’ in men and 12-month dat…”
““We are working with urgency to deliver multiple data milestones in the second half of 2026.”
The positive Phase 2 results from Study ‘207’ marked the first successful clinical demonstration of an oral treatment for female pattern hair loss in the United States and increased our conviction in…
Stated in 2 of 2 supplied quarters. Management reported: “• Patient Enrollment Complete in Study ‘306’ in Females with PHL; Topline Data Anticipated in 1H27: Veradermics has completed enrollment of Study ‘306’, a Phase 2/3 multi-center, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of VDPHL01 at two dose regimens (4.5 mg once-daily and twice-daily) over 52 weeks in 556 female participants with mild-to-moderate pattern hair loss.” “The Company expects to report topline data in the first half of 2027.”
“The positive Phase 2 results from Study ‘207’ marked the first successful clinical demonstration of an oral treatment for female pattern hair loss in the United States and increased our conviction in…”
“Veradermics is actively enrolling patients into Study ‘306’, a Phase 2/3 clinical trial evaluating VDPHL01 in female PHL.”
Veradermics remains well capitalized to execute Exhibit 99.1 against these milestones while continuing preparations for a potential commercial launch, with the goal of establishing VDPHL01, if approv…
Stated in 2 of 2 supplied quarters. Management reported: “Second Quarter 2026 Financial Results • Cash Position: Cash, cash equivalents, and marketable securities totaled $819.9 million as of June 30, 2026 including net proceeds from our follow-on offering completed in the second quarter 2026.” “These proceeds, together with existing cash, cash equivalents and marketable securities, are expected to support Veradermics’ current operating plans into 2030, including multiple anticipated Phase 3 readouts and the potential commercial launch of VDPHL01, if approved.”
“Veradermics remains well capitalized to execute Exhibit 99.1 against these milestones while continuing preparations for a potential commercial launch, with the goal of establishing VDPHL01, if approv…”
“Following our successful IPO and subsequent financing activities, we are well capitalized to execute on these milestones and advance our mission to provide the first-ever FDA-approved non-hormonal or…”
Progress the registration-directed trials in men and women and report clinical data supporting potential approval of VDPHL01 for pattern hair loss.
Maintain the capital position management says will support clinical milestones and potential commercial launch of VDPHL01 through 2030.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
2 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.